OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
November 17, 2021 01:30 ET
|
OSE Immunotherapeutics; FoRT Foundation
Clinical trial sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics.A strategy of combining Opdivo®, a PD-1 targeted...
OSE Immunotherapeutics Presented New Translational Data on Tedopi® and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI®-IL-7
November 16, 2021 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, Nov. 16, 2021 (GLOBE NEWSWIRE) -- November 16, 2021, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented new clinical and translational data on...
OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
November 15, 2021 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, Nov. 15, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first positive preclinical efficacy data on its novel myeloid cell immune...
OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences
October 19, 2021 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Oct. 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that its Chief Scientific Officer Nicolas Poirier will present the latest...
OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
October 13, 2021 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, Oct. 13, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that three abstracts have been accepted for presentation at the Society for...
OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day”
October 12, 2021 01:30 ET
|
OSE Immunotherapeutics
R&D Day to highlight the Company’s strategy on its leading clinical programs and emerging firs-in-class portfolio in immuno-oncology;Presentations by leading clinicians to feature the latest data...
OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
October 11, 2021 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, Oct. 11, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announced today that it has received notice of allowance from the European Patent Office...
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezabenlimab, in Patients with Advanced Endometrium or Colorectal Tumors
September 30, 2021 12:30 ET
|
OSE Immunotherapeutics
Dosing of first patient in the expansion phase triggers a milestone payment of €8 million from Boehringer Ingelheim to OSE Immunotherapeutics.Data from the dose escalation Step 1 of the Phase 1 trial...
OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021
September 27, 2021 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that it will host a virtual and in-person R&D Day on Tuesday, October...
OSE Immunotherapeutics Announces H1 2021 Results and Provides a Corporate Update
September 21, 2021 12:00 ET
|
OSE Immunotherapeutics
Positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) after ICI failure.Positive Phase 1 dose escalation results for BI 765063 (CD47/SIRPα pathway) as monotherapy or in...